Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis

被引：7

作者：

He, Hao-Lan ^{[1
]}

Zhang, Ji-Bin ^{[2
]}

Li, Qian ^{[1
]}

机构：

[1] Cent Hosp, Shenyang Med Coll, Dept Gastroenterol, Shenyang 110024, Liaoning, Peoples R China

[2] Seventh Peoples Hosp Shenyang, Dept Endocrinol, Shenyang 110024, Liaoning, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 23期

关键词：

Ulcerative colitis; Tissue factor; Tissue factor pathway inhibitor; INFLAMMATORY-BOWEL-DISEASE; MATRIX METALLOPROTEINASES; ATHEROSCLEROSIS; PLATELETS; INJURY;

D O I：

10.3748/wjg.v20.i23.7461

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To investigate the clinical significance of expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in ulcerative colitis (UC). METHODS: Thirty UC specimens taken by colonoscopy from patients with active UC treated at the Department of Pathology, Central Hospital Affiliated to Shenyang Medical College from February 2010 to January 2012 were included in an experimental group, and 30 normal colon tissue samples taken by colonoscopy from non-UC patients were included in a control group. Expression of TF and TFPI in UC and normal colon tissue samples was detected by immunohistochemistry. RESULTS: The positive rate of TF in UC was significantly higher than that in normal colon tissue (63% vs 33%, chi(2) = 5.41, P < 0.05). The positive rate of TFPI in UC was also significantly higher than that in normal colon tissue (43% vs 17%, chi(2) = 5.08, P < 0.05). CONCLUSION: Positive rates of TF and TFPI expression in UC are significantly higher than those in normal colon tissue. TF and TFPI may play an important role in the pathogenesis of UC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

引用

页码：7461 / 7465

页数：5

共 29 条

[1] Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review [J].

Vincent, JL ;

Abraham, E ;

Esmon, C ;

Hack, CE .

CRITICAL CARE MEDICINE, 2000, 28 (09) :S33-S33

[2] Vascular endothelial growth factor (VEGF164) ameliorates intestinal epithelial injury in vitro in IEC-18 and Caco-2 monolayers via induction of TGF-β release from epithelial cells [J].

Bulut, K ;

Pennartz, C ;

Felderbauer, P ;

Ansorge, N ;

Banasch, M ;

Schmitz, F ;

Schmidt, WE ;

Hoffmann, P .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (06) :687-692

[3]

Chen J, 2001, THROMB HAEMOSTASIS, V86, P334

[4] PLATELETS CIRCULATE IN AN ACTIVATED STATE IN INFLAMMATORY BOWEL-DISEASE [J].

COLLINS, CE ;

CAHILL, MR ;

NEWLAND, AC ;

RAMPTON, DS .

GASTROENTEROLOGY, 1994, 106 (04) :840-845

[5] Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels [J].

Crawley, JTB ;

Goulding, DA ;

Ferreira, V ;

Severs, NJ ;

Lupu, F .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) :218-224

[6]

Ding WQ, 2001, FUDAN XUEBAO YIXUE B, V7, P330

[7]

Drew AF, 1997, LAB INVEST, V77, P291

[8] Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation [J].

Enkhbaatar, P ;

Okajima, K ;

Murakami, K ;

Uchiba, M ;

Okabe, H ;

Okabe, K ;

Yamaguchi, Y .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1752-1759

[9] Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease [J].

Fägerstam, JP ;

Whiss, PA ;

Ström, M ;

Andersson, RGG .

INFLAMMATION RESEARCH, 2000, 49 (09) :466-472

[10] Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis [J].

Herman, MP ;

Sukhova, GK ;

Kisiel, W ;

Foster, D ;

Kehry, MR ;

Libby, P ;

Schönbeck, U .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) :1117-1126

← 1 2 3 →